Cancer metastasis, the lymphatic system, and aspirin's role

Researchers from Melbourne's Peter MacCallum Cancer Institute believe they have uncovered a pathway for cancer to metastasize that takes advantage of the lymphatic system, and they may have found a way to blunt that avenue.

Their findings have been published in the journal Cancer Cell.

While it has long been understood that roaming cancer cells take advantage of the blood vessels to spread, the Institute's researchers say they've found that cancer cells also use the lymphatic system to metastasize, and that the lymphatic vessels contribute to the spread by dilating and allowing a greater volume of cells to spread throughout the body.

The lymphatic vessels amount to a tumor supply line, but researchers say this is where drugs such as NSAIDs, or non-steroidal anti-inflammatory drugs such as aspirin can play a role in preventing metastasis because they reduce inflammation and reduce the dilation of those vessels, effectively making it much harder for cancer cells to use those vessels for metastasis.

Source: Cancer Cell

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap